Download PDF
kleintier konkret 2014; 17(1): 3-6
DOI: 10.1055/s-0033-1361515
newsletter|industrie|forschung
Enke Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart

Allergischen Juckreiz kortisonfrei behandeln

Wieland Beck
Zoetis Deutschland GmbH
,
Christina Mandel
Zoetis Deutschland GmbH
› Author Affiliations
Further Information

Publication History

Publication Date:
06 March 2014 (online)

Also available at
    Permissions and Reprints All articles of this category
 

  • Literaturverzeichnis

  • 1 Collard T, Fielder A, Zayai J, Stegemann MR. The absorption, distribution, metabolism, and elimination of oclacitinib maleate, a novel Janus Kinase inhibitor, in the dog. J Vet Pharmacol Ther 2012; 35(3): 137-178
    CrossrefGoogle Scholar
  • 2 Cosgrove SB, Wren JA, Cleaver DM et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013; 24(5): 479-487
    CrossrefGoogle Scholar
  • 3 European Medicines Agency. CVMP assessment report for Apoquel . (EMEA/V/C/002688/0000) 2013: 1-20
    Google Scholar
  • 4 Marsella R, Sousa CA, Gonzales AJ, Fadok VA. Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis. JAVMA 2012; 241(2): 194-206
    CrossrefGoogle Scholar
  • 5 Zoetis (2012a): Study Number 1962C-60-10-A02, Field safety and efficacy of oclacitinib compared to placebo for the control of atopic dermatitis in client-owned dogs (Pivotal for US and EU).
    Google Scholar
  • 6 Zoetis (2012b): Study Number 1962C-60-10-A17, Dose confirmation: replacement therapy for dogs removed from field safety and efficacy of oclacitinib compared to placebo for the control of atopic dermatitis in client-owned dogs protocol.
    Google Scholar
  • 7 Zoetis (2012c): Study 5962C-85-08-364 (56364) (pivotal for EU), Efficacy and safety of oclacitinib for the treatment of pruritic dermatoses in dogs.
    Google Scholar
  • 8 Zoetis (2012d): Study 5662C-85-08-363 (56363), Efficacy and safety of oclacitinib compared to Atopica for the treatment of atopic dermatitis in dogs.
    Google Scholar
  • 9 Zoetis (2012e): Study Number 1462N-60-10-A29, Margin of safety study of oclacitinib administered for 26 weeks to adult dogs (new regimen).
    Google Scholar